News
Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for $3.9 billion to enhance its cancer drug business. The acquisition is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback